9/12/00 -
Received Patent Approval in Canada for Fibrostat(TM)
PROCYON BIOPHARMA INC ("PBP-T") - Received Patent Approval in Canada for
Fibrostat(TM)
Procyon BioPharma announced that the Canadian Intellectual Property Office has approved the
patent application, No. 2,132,416, for FIBROSTAT(TM), a topical cream for the treatment of
scars resulting from surgery or burns. Patents have already been issued in the United States,
Australia and Japan, and approval of its patent application is pending in Europe.
FIBROSTAT(TM) addresses the largely unmet medical need of providing relief to patients suffering
from the effects of scarring, pain and irritation following general surgery, plastic surgery and burns.
FIBROSTAT(TM) was invented in Canada at the University of Manitoba by plastic surgeon, Dr.
Ken Dolynchuk, and is exclusively licensed to Procyon BioPharma. In February 2000, Procyon
BioPharma and Biovail Corporation announced a licensing agreement for the Canadian marketing of
FIBROSTAT(TM). The annual Canadian market potential for FIBROSTAT(TM) is estimated at
$25 million and the world market potential is expected to exceed $500 million.
Procyon BioPharma Inc. is a publicly listed, biopharmaceutical Company focused principally on
advancing two powerful platform technologies that have the potential to diagnose and treat cancer.
Procyon''s non-pathogenic Antinuclear Autoantibodies (ANAs) bind specifically to multiple cancer
cell types strongly enhancing the immune response to cancer cells. Prostate Secretory Protein
(PSP(94)) is a naturally occurring human protein that has the potential to treat prostate cancer by
inhibiting abnormal prostate cell growth. In addition, the estimation of PSP(94) levels in prostate
cancer patients may have prognostic and diagnostic applications. Procyon also has two late-stage
products: FIBROSTAT(TM), a topical cream for the management of newly formed scars following
surgery or burns and COLOPATH(TM), a rapid, non-invasive screening test for colorectal cancer.
Procyon''s shares trade on the Toronto Stock Exchange under the ticker symbol, PBP. TEL: (514)
685-9283
Procyon BioPharma Inc. |
